Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToleroMune HDM Tolerability Study
NCT01949441Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Sep 2013
- Primary completion
- May 2014
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of HDM-SPIRE in house dust mite allergy, asthma, Rhinoconjunctivitis (RC), sponsored by NIOX Group. Started Sep 2013; status: completed.
02
Drugs
HDM-SPIRE
03
Conditions
house dust mite allergyasthmaRhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT01949441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949441.